The second hearing aid of its type to be approved by the US Food and Drug Administration (FDA) for direct-to-consumer sales in the US is taking its first steps towards the future US over-the-counter (OTC) sales channel.
Australian-based Nuheara, which has so far mostly concerned itself with the market for earbuds with different degrees of hearing enhancing technology, has recently begun a clinical trial to test the safety and effectiveness of its newly developed series of hearing aid products, it writes in a press release. In August, the company aired its plans to have its product series Iqbuds clinically validated and approved.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.